MBKEYMB@EC2611A

Canonic-B Profit Forecast Upgraded Due to Gilead's Acquisition of Ouro Medicines

KEYMED BIO-B released FY2025 9 Months earnings on March 26 (BJT), actual revenue HKD 658.94 M, actual EPS HKD -1.18

KEYMED BIO-B released FY2025 Q3 earnings on March 26, 2026 (BJT), with actual revenue of HKD 118.92 M and EPS of HKD -0.8552

CMHK-B Revenue Grew by 67% in 2025 but Parent Company Loss Expanded

KEYMED BIO-B released FY2025 Q4 earnings on March 26 During-Market (BJT), actual revenue HKD 120.97 M, actual EPS HKD -0.872

KEYMED BIO-B released FY2025 earnings on March 26 During-Market (BJT), actual revenue HKD 782.9 M (forecast HKD 893.82 M), actual EPS HKD -2.0849 (forecast HKD -2.1456)

KEYMED BIO-B to Release FY2025 Earnings on March 26 During-Market (BJT), Forecast Revenue HKD 909.18 M, EPS HKD -2.1826

Conuma-B Receives AZD0901 Phase III Clinical Trial Milestone Payment

Guojin Securities First Coverage of CanNova-B with a Buy Rating

Guo Jin Securities Reports Positive Outlook for Canomena-B

Conuma's Self-Developed New Drug Supicibai Monoclonal Antibody Injection (Kangyueda®) Included in the National Medical Insurance Catalogue

Pacific Securities Gives BUY Rating to CanNova-B

Significant Progress Achieved by Sanofi and Canonic's Dual Antibody Drugs in Respiratory and Autoimmune Diseases

Huatai Securities Maintains Buy Rating on CanNova Biologics Stock

Conuma-B's Self-Developed Drug CM512 I Phase Clinical Trial for Atopic Dermatitis Successful

Goldman Sachs Initiates Coverage of CanNova with Buy Rating

IL-4Rα Monoclonal Antibody Market Faces New Competitive Landscape

Knomia's Supiquibam Antibody Commercialization Boosts Profits and Initiates New Drug Phase III Trial

Lin gives a moderate buy recommendation for Keymed Biosciences

Supichibai Antibody Stands Out in Allergic Rhinitis Treatment

SOMERLEY CAP

TIANLI HOLDINGS

CPM GROUP

FUTONG TECH

NICHE-TECH SEMI

SINO ICT

COSMOS MACH

UBOT HOLDING

SAMPLE TECH

PERENNIAL INT'L

520690

159506

159849

516500

159102

02162

159615

513120

KeyBanc analyst maintained a Buy rating on Keymed Biosciences, Inc. yesterday and set a price target of HK$87.31.End of Quarter Sale - 50% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Currently, the analyst consensus on Keymed Biosciences, Inc. is a Strong Buy with an average price target of HK$85.48.

Tip Ranks

Bosera Hang Seng SCHK Innovative Drug Select ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

China Merchants CSI Biotechnology Theme ETF

E Fund Hang Seng SCHK Innovative Drug ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

ChinaAMC CSI Biotechnology Theme ETF

First Trust NYSE Arca Biotech Index Fd

Huaan Hang Seng Biotech ETF

KEYMED BIO-B

China Southern Hang Seng Biotech ETF(QDII)

Penghua SSE STAR Biology and Medicine ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Guotai CSI Bio-medicine ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

KeyBanc Sticks to Their Buy Rating for Keymed Biosciences, Inc. (2162)

560600

516820

159859

159837

516930

588860

KEYMED BIO-B announced its 2025 annual results, with revenue recorded at RMB 716 million, an increase of 67.3% year-on-year. The loss slightly widened from RMB 515 million in the previous year to RMB 523 million, with a loss per share of RMB 1.91. No final dividend will be distributed

AASTOCKS

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Tianhong CNI BIOMEDICINE ETF

E Fund CSI Biotechnology Theme ETF

Minsheng Royal CSI Biotechnology Theme ETF

ICBCCS SSE STAR Biology and Medicine ETF

"Performance" KEYMED BIO-B's annual loss slightly widened to 523 million RMB

Keymed Biosciences (HKEX: 02162) reported its 2025 annual results, with total revenue of approximately RMB 720 million, a 67% increase year-on-year. Key revenue sources included RMB 310 million from its core product Kangyueda® and RMB 410 million from collaborations. The company maintained R&D expenses of around RMB 720 million and had cash reserves of approximately RMB 1.96 billion. New drug applications for Kangyueda® have been approved, enhancing patient access in China. Additionally, CMG901 was out-licensed to AstraZeneca, and CM336 was out-licensed to Ouro Medicines, with potential payments totaling approximately US$320 million for Keymed.

prnewswire

09:54 ETKeymed Biosciences Announces 2025 Annual Results and Business Updates

513060

The Huatai Securities report points out that the acquisition deal between KEYMED BIO-B and Gilead reflects its platform value. Gilead will make an upfront payment of $1.675 billion and a $500 million milestone acquisition of Ouro, while KEYMED will receive $250 million as an upfront payment and $70 million in milestones, and will continue to enjoy sales sharing rights for CM336. The firm believes this transaction will accelerate the global value realization of CM336 and reiterates its optimism regarding KEYMED's related assets, maintaining a "Buy" rating with a target price of 91.08 yuan

iShares Global Healthcare

Bosera Hang Seng Health Care ETF(QDII)

iShares US Pharma

Direxion S&P Biotech Bull 3X

Gilead Sciences

Yinhua CSI Innovative Drugs Industry ETF

SPDR S&P Biotech

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

Gilead Sciences, Inc.

ALPS Medical Breakthrough

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

E Fund CSI 300 Health Care ETF

Invesco Nasdaq Biotechnology ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Penghua CSI HK Connect Health Care Composite ETF

Ark Genomic Revolution ETF

VG Health

Health Care Select Sector SPDR

Huatai Securities: Gilead's acquisition of Ouro reflects the value of the KEYMED platform

02720

09899

08299

01773

03880

09959

00290

02629

01440

RIDGE OUTDOOR(02720) fell 24.95%, with a trading turnover 35.0 Million HKD, and a year-to-date rose 132.8%. NETEASE MUSIC(09899) fell 9.62%, with a trading turnover 488.4 Million HKD, and a year-to-date fell 11.1%. GT GOLD(08299) fell 7.69%, with a trading turnover 53.7 Million HKD, and a year-to-date rose 17.6%.

Top Gainers&Losers

RIDGE OUTDOOR

NETEASE MUSIC

GT GOLD

TIANLI INT HLDG

Medtide Inc.

LINKLOGIS-W

GOFINTECH QUANT

MIRXES-B

STAR SHINE HLDG

Top 10 HK Stock Losers (2.12)

Guojin Securities initiates coverage on KEYMED BIO-B with a "Buy" rating and a target price of HKD 83.29. It forecasts operating revenues of RMB 661 million, RMB 1.255 billion, and RMB 2.064 billion for 2025 to 2027, with annual growth rates of 54%, 90%, and 65%, respectively. Dupilumab, as the second IL-4R monoclonal antibody globally and the first in China, has been included in the national medical insurance catalog, expected to be implemented in early 2026, with sales expected to grow rapidly

Guotai Junan Securities initiates coverage on KEYMED BIO with a "Buy" rating and a target price of 83.29 yuan